Treatment(s) now being considered-Bone marrow transplant Posts on Medivizor
Navigation Menu

Treatment(s) now being considered-Bone marrow transplant Posts on Medivizor

Evaluating the use of high-dose chemotherapy for the treatment of patients with high-risk relapsed Hodgkin lymphoma.

Evaluating the use of high-dose chemotherapy for the treatment of patients with high-risk relapsed Hodgkin lymphoma.

Posted by on Jun 13, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to evaluate high-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) for the treatment of patients with high-risk relapse (HRR) classical Hodgkin’s lymphoma (cHL). The authors concluded that the outcomes of patients with HRR cHL have improved over the last 15 years with...

Read More

How effective is involved field radiotherapy after autologous hematopoietic stem-cell transplantation in patients with high-risk relapsed/refractory lymphoma?

How effective is involved field radiotherapy after autologous hematopoietic stem-cell transplantation in patients with high-risk relapsed/refractory lymphoma?

Posted by on Apr 4, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell The authors assessed the safety and efficacy of involved-field radiotherapy (IFRT) after autologous hematopoietic stem-cell transplantation (ASCT) in patients with high-risk relapsed/refractory (r/r) lymphoma. The study found that IFRT given soon after ASCT provided durable responses and was well tolerated in these patients. Some...

Read More

Relapsed or refectory Hodgkin’s lymphoma: how does therapy after autologous transplant impact patient outcomes?

Relapsed or refectory Hodgkin’s lymphoma: how does therapy after autologous transplant impact patient outcomes?

Posted by on Jan 17, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study reviewed treatment options to improve the outcomes of patients with Hodgkin’s lymphoma (HL) treated with an autologous stem cell transplant (ASCT).  Some background HL is a type of blood cancer. Patients with HL who do not respond to chemotherapy are given a transplant of their own healthy stem cells. The...

Read More

The effects of tandem autologous-reduced intensity allogeneic stem cell transplantation in patients with high-risk relapsed Hodgkin lymphoma

The effects of tandem autologous-reduced intensity allogeneic stem cell transplantation in patients with high-risk relapsed Hodgkin lymphoma

Posted by on Dec 26, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell The study evaluated outcomes of tandem autologous stem cell transplantation (ASCT) – reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (alloSCT) in patients with high-risk (HR) relapsed Hodgkin lymphoma (HL). The main finding was that this approach was safe and effective in such patients. Some...

Read More

Anti-PD1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma

Anti-PD1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma

Posted by on Oct 18, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell The study evaluated outcomes of anti-programmed cell death-1 monoclonal antibodies (anti-PD-1-mAbs or APMs) before and after allogeneic hematopoietic cell transplantation (alloHCT) for patients with relapsed/refractory Hodgkin lymphoma (r/r-HL). The authors found that patients receiving APMs before alloHCT had frequent immune-related...

Read More

How effective and safe is high-dose chemotherapy and stem cell transplant for children with lymphoma?

Posted by on Apr 14, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined the effectiveness and safety of high-dose chemotherapy and stem cell transplants for children with lymphoma. The study showed that the combination treatment was very effective but that the dose may need to be adjusted for some patients. Some background Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL)...

Read More

Can a stem cell transplant improve outcomes of patients with cHL after nivolumab treatment?

Posted by on Feb 29, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of a stem cell transplant after nivolumab (Opdivo) therapy in patients with classical Hodgkin’s lymphoma (cHL) that came back or stopped responding to treatment. This study concluded that nivolumab followed by stem cell transplant is safe and effective for these patients. Some background...

Read More

What factors can predict the success of stem cell transplantation for patients with lymphoma?

Posted by on Nov 3, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the risk factors associated with delayed engraftment in patients who had stem cell transplantation (SCT). The authors found that patients receiving blood transfusions, those with low platelet levels, and those given low numbers of stem cells during SCT were more likely to experience DE. Some...

Read More

Evaluating outcomes after haploSCT for patients with classical Hodgkin lymphoma

Posted by on Jun 25, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of patients with classical Hodgkin lymphoma (cHL) after reduced-intensity chemotherapy and haploidentical stem cell transplantation (haploSCT). This study concluded that this treatment approach is as effective as allogeneic SCT (alloSCT), but with fewer long-term complications. Some background...

Read More